Measuring blood flow during liver embolization procedures

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This research evaluates a new technique called quantitative digital subtraction angiography (qDSA) to measure blood flow in patients undergoing liver embolization procedures. The goal is to ensure that the blood flow to liver tumors is effectively reduced by calculating blood flow before, during, and after the embolization. Up to 20 participants will be enrolled for a single study visit, with data collection extending for up to six months. This innovative approach aims to enhance the precision of liver cancer treatments.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Give voluntary, written informed consent to participate in this study and willing to comply with study-related evaluation and procedure schedule

Exclusion Criteria:

* Pregnancy or breastfeeding
* Patients with an acute kidney injury or stage IV or V chronic kidney disease (Cr greater than 2.4 or estimated glomerular filtration rate (eGFR) less than 30), unless anuric and on dialysis without expected return of renal function.
* Patients with an iodinated contrast allergy who cannot be adequately premedicated to receive contrast as part of the embolization procedure.
* Patients with a physical or psychological condition that would impair study participation.
* The patient is judged unsuitable for study participation by the Investigator for any other reason

Where it's running

• UW Hospital and Clinics
  Madison, Wisconsin, United States Recruiting

Study contacts

• Principal investigator: Paul Laeseke, MD, PhD — UW School of Medicine and Public Health
• Study coordinator: Radiology Coordinators
• Email: Radstudy@uwhealth.org
• Phone: 608-282-8349

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Scout-dose check using resin microspheres before yttrium-90 treatment for liver tumors

  This test tries a small 'scout' dose of the same resin microspheres used in yttrium-90 treatment to better measure lung shunt in adults with liver cancer or liver metastases.

  Recruiting Seoul National University Hospital · Seoul · NCT07476651

• Adjuvant TACE after curative liver cancer surgery for patients with high-risk recurrence features

  This trial will see if giving TACE after curative liver surgery lowers the chance the cancer comes back in people who have high-risk features for recurrence.

  Recruiting Phase 3 Guangxi Medical University · Nanning · NCT07417397

• Drug-eluting bead transarterial chemoembolization for large recurrent or refractory DLBCL masses

  This retrospective study will try drug-eluting bead transarterial chemoembolization (DEB-TACE) to shrink and control large recurrent or refractory DLBCL masses in adults.

  Recruiting Fujian Medical University · Fuzhou, Fujian · NCT07198230

• Collecting data on treatment effectiveness and safety for patients with advanced liver cancer

  This study is testing how well a combination of a specific cancer treatment and immunotherapy works for patients with advanced liver cancer who haven't been treated before or have had their cancer come back.

  Recruiting Sun Yat-sen University · Guangzhou, Guangdong · NCT06788353

• Ablative radioembolization for localized hepatocellular carcinoma beyond the Up-To-7 criteria

  This study is testing a new treatment using Yttrium-90 glass microspheres for people with localized liver cancer that doesn't meet certain criteria to see if it helps shrink tumors and improve survival.

  Recruiting at 7 sites Phase 2 Seoul National University Hospital · Gangneung, Gangwon-do and 7 other locations · NCT06773845

• High-dose Y-90 radioembolization for large kidney tumors

  This test uses high-dose Y-90 radioembolization to try to shrink or control kidney tumors larger than 4 cm in people who cannot have surgery.

  Recruiting Phase 2 Western University, Canada · London, Ontario · NCT06642220

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.